If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
In arthropods such as insects, wound healing following injury and coagulation of body fluid involves a process of melanisation of the scab, migration of cells to the scab area, and a degree of repair of the cuticle (which serves as an exoskeleton), in locusts restoring it to 2/3 of its original strength. Several vertebrates including lizards and salamanders shed their tails (autotomy) when attacked by a predator, especially if the tail is grasped, giving the animal a chance to escape. The tail is at least partially regrown over a period of weeks or months.
Lance Henriksen at IMDb Lance Henriksen at the TCM Movie Database (archived) Lance Henriksen at the Internet Broadway Database Films in Review interview Archived September 9, 2018, at the Wayback Machine
Unlike aerated chocolates produced with large bubbles, micro-aerated chocolate has nitrogen beaten into the mixture. The resulting chocolate, different not only in bubble size but also flavour and texture. This is theorised to arise from the gas having a different solubility. Aerated chocolates containing long tubes of air are also created using this technique, but their distinction comes from how the aerated chocolate is extruded rather than set in a moulded shell. The final type, those held together by a skeleton of solid particles, are produced using water evaporation methods. In the first of these, sugar is dissolved in water. This solution is emulsified with cocoa liquor and milk solids, which is evaporated and then dried using industrial machinery, until the product contains less than 2% water. In the second, water is emulsified with liquid chocolate and set and then freeze dried, removing the water.
== Early life == On August 13, 1930, Walter David and Addie Turner Mizell welcomed their son Wilmer David into the world. Contrary to popular belief (caused by his nickname), Wilmer was actually born and raised in Leakesville, Mississippi, though the town of Vinegar Bend, Alabama was only a few miles away. His father died when he was two, and his grandmother and uncle brought him up, as his mother was sickly. He grew up laboring on the family farm, which produced fruit and vegetables. The Mizells also raised hogs and cattle. Additional income for Wilmer came from hauling wood, logging, and tapping turpentine from pine trees. "I walked behind more mules than I walked batters – and that's saying a lot," he later reflected, comparing his childhood with his career. Growing up, Mizell was unable to play catch with his brother because he was such an erratic thrower. He practiced his control by throwing at a smokehouse knothole, eventually knocking the door in because of all his practice. At the age of 16, he started playing for baseball teams, pitching in Sunday leagues around Vinegar Bend. The St. Louis Cardinals held a tryout camp in Biloxi, Mississippi, in 1948, and Mizell recorded three strikeouts before a thunderstorm ended it early. Impressed with the youngster, scout Buddy Lewis visited him the following year in Lakeville. Mizell, returning from a local swimming spot, impressed Lewis again with his fastball, and the scout promised to sign him for $500 upon his graduation from Leakeville High School, which would occur later that evening.
small nucleolar RNA (snoRNA) A class of small non-coding RNA molecules whose primary function is to direct the post-transcriptional modification of other RNAs, mainly transfer RNAs (tRNA), small nuclear RNAs (snRNA), and especially ribosomal RNAs (rRNA) as a part of ribosome synthesis in the nucleolus. SnoRNAs contain antisense sequences that complement sequences within these target RNAs and guide ribonucleoprotein complexes to them, which can then catalyze specific nucleoside modifications, typically methylation or pseudouridylation.
Sources: en.wikipedia.org
The true identity of the discoverers of carbon nanotubes is a subject of some controversy. A 2006 editorial written by Marc Monthioux and Vladimir Kuznetsov in the journal Carbon described the origin of the carbon nanotube. A large percentage of academic and popular literature attributes the discovery of hollow, nanometre-size tubes composed of graphitic carbon to Sumio Iijima of NEC in 1991. His paper initiated a flurry of excitement and could be credited with inspiring the study of many applications of carbon nanotubes. Though Iijima has been given much of the credit for discovering carbon nanotubes, it turns out that the timeline of carbon nanotubes goes back much further than 1991.
=== 3 July === Eight people were killed and at least 50 others were injured in Russian airstrikes in Dnipro. One person was killed in a missile attack near Poltava. Russian forces claimed to have taken the Novy district of Chasiv Yar. In Russia, the mayor of Novorossiysk, Andrey Kravchenko, reported that Ukrainian naval drones attacked the city's port but were repelled.
Some states also require completion of a specified number of continuing education contact hours prior to issuing or renewing a license. Licensing is somewhat controversial as it adds a bureaucratic layer in a field that is severely understaffed. Simply requiring testing personnel to obtain and maintain their national certification would help ensure competent testing personnel without increasing costs to testing personnel. Some states recognize another state's license if it is equal or more stringent, but currently California does not recognize any other state license.
== Chemistry == Etifoxine is a nonbenzodiazepine—that is, it is similarly a GABAA receptor positive allosteric modulator but its chemical structure is distinct from that of benzodiazepines. Instead, it is a benzoxazine derivative.
== Legal status == As of October 2015, β-hydroxythiofentanyl is a controlled substance in China. As of May 2016, β-hydroxythiofentanyl was temporarily listed as a Schedule I controlled substance in the United States. A final ruling placing it in Schedule I was issued by the DEA on May 8, 2019 after a 1 year notice of proposed permanent scheduling. There were no petitions for hearings on the matter.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.